In this In Vivo podcast, David Wild speaks with Adrian Woolfson, co-founder, president and CEO of Genyro, about how high-fidelity DNA writing and AI-driven genome design could reshape biopharma R&D, from accelerating program design and iteration speed to enabling civilizational-scale applications like DNA-based data storage and ultra-fast vaccine manufacturing. Woolfson, a physician-scientist, explains why Genyro is pursuing a licensing-led business model and which transformative applications he believes will emerge first.